Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH2] in postmenopausal women with osteoporosis

Clinical Pharmacokinetics

Volumn 52, Issue 11, 2013, Pages 995-1004

  Sturmer, Amy ^a   Mehta, Nozer ^a   Giacchi, Jenna ^a   Cagatay, Tulin ^a   Tavakkol, Roxanne ^a   Mitta, Sheela ^a   Fitzpatrick, Lorraine ^b   Wald, Jeff ^b   Trang, John ^c   Stern, William ^a  

^a Unigene Laboratories Incorporated   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PK/PD International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; TERIBONE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERIC COATED TABLET; ESTONIA; FEMALE; HUMAN; LUMBAR SPINE; MORNING DOSAGE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; POSTMENOPAUSE; RECOMBINANT PROTEINS; TERIPARATIDE;

EID: 84886770534     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0083-4     Document Type: Article

References (16)

1. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-61.
2. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-26.
3. Verhaar HJ, Lems WF. PTH analogs and osteoporotic fractures. Expert Opin Biol Ther. 2010;10:1387-94.
4. Karsdal MA, Henriksen K, Bay-Jensen AC, et al. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. J Clin Pharmacol. 2011;51:460-71.
5. Satterwhite J, Heathman M, Miller PD, et al. Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis. Calcif Tissue Int. 2010;87(6):485-92.
6. Fraher LJ, Avram R, Watson PH, et al. Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH(1-34) in healthy humans. J Clin Endocrinol Metab. 1999;84:2739-43.
7. Neugebauer W, Barbier J-R, Sung J, et al. Solution structure and adenylyl cyclase stimulation activities of C-terminal truncated human parathyroid hormone analogues. Biochemistry. 1995;34:8835-42.
8. Mehta N, Erickson K, Stern W, et al. Pharmacokinetic clinical studies of an orally delivered recombinant PTH analog. J Bone Miner Res. 2009;24(Suppl 1):1249.
9. Whitfield J, Morley P, Langille R, et al. Adenyl cyclase-activating anabolic agents. In: Whitfield JF, Morley P, editors. Parathyroid hormone and prostaglandins E in anabolic treatments for osteoporosis. CRC Press LLC; 1998.
10. Eli Lilly and Company. Forteo Product Information; 2010.
11. Perron 2001. Teriparatide injection (rDNA origin). US Food and Drug Administration Documents Management. Updated February 1, 2010. http://www.fda.gov/ohrms/dockets/ac/01/slides/3761s2-01-lilly/sld078.htm.
12. Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the safety and efficacy of oral human parathyroid hormone [rhPTH(1-31)NH2] compared to teriparatide in postmenopausal women with osteoporosis. Bone. 2013;53:160-6.
13. Daddona PE, Matriano JA, Mandema J, et al. Parathyroid hormone (1-34)-coated microneedle patch sytem: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res. 2010;28:159-65.
14. Fujita T, Inoue T, Morii H. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int. 1999;9(4):296-306.
15. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. JCEM. 2012;97(2):311-25.
16. Fitzpatrick LA, Dabrowski DE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2011;96(8):2441-9.